Article
Oncology
Hideki Iwamoto, Takashi Niizeki, Hiroaki Nagamatsu, Kazuomi Ueshima, Takako Nomura, Teiji Kuzuya, Kazuhiro Kasai, Yohei Kooka, Atsushi Hiraoka, Rie Sugimoto, Takehiro Yonezawa, Akio Ishihara, Akihiro Deguchi, Hirotaka Arai, Shigeo Shimose, Tomotake Shirono, Masahito Nakano, Shusuke Okamura, Yu Noda, Naoki Kamachi, Miwa Sakai, Hiroyuki Suzuki, Hajime Aino, Norito Matsukuma, Satoru Matsugaki, Kei Ogata, Yoichi Yano, Takato Ueno, Masahiko Kajiwara, Satoshi Itano, Kunitaka Fukuizumi, Hiroshi Kawano, Kazunori Noguchi, Masatoshi Tanaka, Taizo Yamaguchi, Ryoko Kuromatsu, Atsushi Kawaguchi, Hironori Koga, Takuji Torimura
Summary: The study found that local treatment with New-FP is potentially superior to systemic treatment with sorafenib as an initial treatment for locally progressed HCC without extrahepatic spread.
Review
Gastroenterology & Hepatology
Yin Long, Xingdong Song, Yan Guan, Ran Lan, Ziqi Huang, Senlin Li, Lei Zhang
Summary: This systematic review found that the combination of sorafenib and hepatic arterial infusion chemotherapy (HAIC) improved overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) compared with sorafenib alone in advanced hepatocellular carcinoma (HCC), with an acceptable safety profile.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Oncology
Meiyue Li, Shen Lin, Leslie Wilson, Pinfang Huang, Hang Wang, Shubin Lai, Liangliang Dong, Xiongwei Xu, Xiuhua Weng
Summary: The study evaluated the cost-effectiveness of HAIC plus sorafenib (SoraHAIC) versus standard care for HCC patients from the Chinese health system perspective. The results indicated that SoraHAIC was not cost-effective in medium- and low-income regions of China, but there was a 38.8% probability that it would be cost-effective in developed areas (such as Beijing).
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Yuki Zaizen, Masahito Nakano, Kazuta Fukumori, Yoichi Yano, Kota Takaki, Takashi Niizeki, Kotaro Kuwaki, Masaru Fukahori, Takahiko Sakaue, Sohei Yoshimura, Mika Nakazaki, Ryoko Kuromatsu, Shusuke Okamura, Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Yu Noda, Naoki Kamachi, Hironori Koga, Takuji Torimura
Summary: Clinical studies have shown that immunotherapy is more effective than sorafenib for advanced hepatocellular carcinoma, but the outcomes of HAIC with cisplatin compared to sorafenib remain unclear. This study found that HAIC with cisplatin significantly prolonged overall survival for intrahepatic advanced HCC, particularly for patients in Child-Pugh class A.
Article
Oncology
Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
Summary: For locally advanced HCC after LD-CCRT, the clinical efficacies of sequential treatment with HAIC and sorafenib were comparable in terms of overall survival, progression-free survival, and treatment response rates. Both treatment options showed similar results in terms of radiological objective response rate and conversion rate to surgical resection or liver transplantation. However, the HAIC group had worse profiles in terms of leukopenia and hypoalbuminemia as compared to the Sorafenib group in terms of treatment-related adverse events.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2021)
Article
Oncology
Chao An, Mengxuan Zuo, Wang Li, Qifeng Chen, Peihong Wu
Summary: This study compared the effectiveness of hepatic arterial infusion chemotherapy (HAIC) and transarterial chemoembolization (TACE) in patients with infiltrative hepatocellular carcinoma (HCC) and found that HAIC significantly improved overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR) compared to TACE. A nomogram model including various factors showed good predictive accuracy and outperformed other staging systems and conventional indices.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Run-Bin Liang, Yang Zhao, Min-Ke He, Dong-Sheng Wen, Xiao-Yun Bu, Ye-Xing Huang, Zhi-Cheng Lai, Yu-Jie Xu, Anna Kan, Wei Wei, Yao-Jun Zhang, Min-Shan Chen, Rong-Ping Guo, Qi-Jiong Li, Ming Shi
Summary: The study demonstrated that in patients with advanced hepatocellular carcinoma, using HAIC plus sorafenib may improve overall survival and progression free survival compared to HAIC alone. Additionally, the combination therapy showed a higher disease control rate in the patients.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Hyeon-Jong Kim, Seung Hyuk Lee, Hyun Jeong Shim, Hyun Jin Bang, Sang Hee Cho, Ik-Joo Chung, Eu Chang Hwang, Jun Eul Hwang, Woo Kyun Bae
Summary: The study results indicate that hepatic arterial infusion chemotherapy (HAIC) may improve overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in patients with hepatocellular carcinoma (HCC), potentially enhancing survival outcomes and treatment response rates for these patients. However, the impact on disease control rate (DCR) is uncertain, requiring further clinical trials to confirm.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Leye Yan, Junqing Lin, Kun Ke, Zhengzhong Wu, Jingyao Huang, Ning Huang, Weizhu Yang
Summary: Hepatic arterial infusion chemotherapy showed superior efficacy and safety compared to sorafenib for advanced hepatocellular carcinoma (HCC), making it a recommended treatment option for suitable patients.
TRANSLATIONAL CANCER RESEARCH
(2022)
Review
Chemistry, Multidisciplinary
Takahiro Yamasaki, Issei Saeki, Yurika Kotoh-Yamauchi, Ryo Sasaki, Norikazu Tanabe, Takashi Oono, Takashi Matsuda, Takuro Hisanaga, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami, Yutaka Suehiro, Isao Sakaida
Summary: The study discussed the clinical benefits of hepatic arterial infusion chemotherapy (HAIC) compared to sorafenib in treating patients with hepatocellular carcinoma (HCC), including the ability to treat a wider range of patients, minimal impact on Child-Pugh scores, and higher efficacy in patients with vascular invasion.
APPLIED SCIENCES-BASEL
(2021)
Review
Oncology
Wei Zhang, Deliang Ouyang, Zhangkan Huang, Xu Che
Summary: This study compared the efficacy of hepatic artery infusion chemotherapy (HAIC) versus sorafenib in patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombus (PVTT). The results showed that HAIC group had significantly higher rates of complete response, partial response, objective response rate, and disease control rate compared to the sorafenib group. Moreover, the overall survival and progression-free survival rates were significantly higher in the HAIC group.
FRONTIERS IN ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Ching-Tso Chen, Tsung-Hao Liu, Yu-Yun Shao, Kao-Lang Liu, Po-Chin Liang, Zhong-Zhe Lin
Summary: Hepatic artery infusion chemotherapy (HAIC) is a well-established treatment for advanced hepatocellular carcinoma (HCC) in East Asia, but lacks international recognition. Evidence supporting its overall survival benefits compared to standard treatments is insufficient. Future research needs to standardize key factors to reveal the clinical value of HAIC-based treatments for HCC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Mei Li, Kai Zhang, Ji'an He, Weihao Zhang, Tianye Lv, Li Wang, Wenge Xing, Haipeng Yu
Summary: In recent years, hepatic arterial infusion chemotherapy (HAIC) has gained popularity in the treatment of hepatocellular carcinoma. This bibliometric analysis examines the cooperation and influence among countries, institutions, authors, and journals in the field of HAIC. The results show that the use of HAIC in HCC treatment is on the rise, particularly in combination with targeted therapy or immunotherapy.
FRONTIERS IN ONCOLOGY
(2023)
Review
Gastroenterology & Hepatology
Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
Summary: Recently, there has been significant development in the treatments for unresectable hepatocellular carcinoma (HCC). Systemic chemotherapy drugs have been approved and recommended worldwide, but their effectiveness is unsatisfactory for certain tumor conditions. Hepatic arterial infusion chemotherapy (HAIC) is a traditional treatment for advanced HCC, and although its survival benefit has not been conclusively proven, accumulating clinical evidence suggests its effectiveness. A multidisciplinary therapeutic strategy combining locoregional HAIC treatment with sequential drug therapy is proposed to achieve cancer-free status through conversion therapy.
CLINICAL AND MOLECULAR HEPATOLOGY
(2023)
Review
Oncology
Takahiro Yamasaki, Issei Saeki, Yurika Yamauchi, Toshihiko Matsumoto, Yutaka Suehiro, Tomokazu Kawaoka, Shinsuke Uchikawa, Akira Hiramatsu, Hiroshi Aikata, Kazufumi Kobayashi, Takayuki Kondo, Sadahisa Ogasawara, Tetsuhiro Chiba, Taro Takami, Kazuaki Chayama, Naoya Kato, Isao Sakaida
Summary: Sarcopenia is associated with poor clinical outcomes in HCC patients receiving sorafenib or lenvatinib. The MS score, based on the positivity of three prognostic factors including skeletal MM, can be a reliable indicator of prolonged survival in patients receiving sorafenib.
Article
Gastroenterology & Hepatology
Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Ann-Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos Lopez Lopez, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong-Won Park, Daniel Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni
Summary: The study aimed to validate objective response as an independent predictor of overall survival (OS) in individuals with unresectable hepatocellular carcinoma (HCC) receiving systemic anti-angiogenic therapy. The results showed that objective response assessed by investigator-assessed mRECIST could predict the survival of patients. Further studies are needed to confirm this finding.
JOURNAL OF HEPATOLOGY
(2023)
Article
Oncology
Philippe Merle, Masatoshi Kudo, Stanimira Krotneva, Kirhan Ozgurdal, Yun Su, Irina Proskorovsky
Summary: This study compared the efficacy and safety of regorafenib and cabozantinib in the second-line treatment of advanced hepatocellular carcinoma. The results showed that regorafenib had a favorable overall survival, lower rates of dose reduction and treatment discontinuation due to adverse events, and lower rates of severe diarrhea and fatigue compared to cabozantinib.
Article
Radiology, Nuclear Medicine & Medical Imaging
Naoshi Nishida, Masatoshi Kudo
Summary: With the development of advanced methods for diagnosis and treatment, the complexity of medical data has increased, leading to the potential for misinterpretation and serious consequences. Artificial intelligence (AI) can help avoid human errors and has shown promising results in diagnosing and managing liver diseases. This paper summarizes recent advances in AI for liver disease and introduces the use of AI in diagnosing liver tumors using B-mode ultrasonography.
Article
Oncology
Andrea Casadei-Gardini, Margherita Rimini, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, Lorenza Rimassa, Jose Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Tiziana Pressiani, Margarida Montes, Caterina Vivaldi, Caterina Solda, Fabio Piscaglia, Atsushi Hiraoka, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Massimo Iavarone, Giovanni Di Costanzo, Fabio Marra, Mario Scartozzi, Emiliano Tamburini, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Valentina Burgio, Mara Persano, Angelo Della Corte, Francesca Ratti, Francesco De Cobelli, Luca Aldrighetti, Stefano Cascinu, Alessandro Cucchetti
Summary: This retrospective multi-center study compared the clinical efficacy and safety of lenvatinib and atezolizumab plus bevacizumab as a first-line treatment for unresectable HCC. The results showed that atezolizumab plus bevacizumab did not have a significant survival advantage over lenvatinib overall. However, lenvatinib had a higher overall survival rate in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease, while atezolizumab plus bevacizumab had a higher overall survival rate in patients with viral hepatitis. After adjusting for population, atezolizumab plus bevacizumab provided better safety profile for most adverse events.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Gastroenterology & Hepatology
Naoya Kato, Masatoshi Kudo, Kaoru Tsuchiya, Atsushi Hagihara, Kazushi Numata, Hiroshi Aikata, Yoshitaka Inaba, Shunsuke Kondo, Kenta Motomura, Naohiro Okano, Masafumi Ikeda, Manabu Morimoto, Shingo Kuroda, Akiko Kimura
Summary: Cabozantinib demonstrated efficacy and manageable safety profile in Japanese patients with advanced HCC. The median PFS was 7.4 months in the prior-sorafenib cohort and 3.6 months in the sorafenib-naive cohort. Disease control rate was 85.0% and 64.3% in the prior-sorafenib and sorafenib-naive cohorts, respectively. The most common adverse events were palmar-plantar erythrodysesthesia syndrome, diarrhea, hypertension, and decreased appetite. No new safety concerns were identified.
HEPATOLOGY RESEARCH
(2023)
Editorial Material
Oncology
Masatoshi Kudo
Review
Oncology
Yasunori Minami, Naoshi Nishida, Masatoshi Kudo
Summary: This article discusses the imaging characteristics and differential diagnosis of hepatocellular carcinoma and other hypervascular liver lesions. Artificial intelligence in medical imaging analysis shows promise as a decision support tool, but further validation is needed.
Review
Oncology
Arndt Vogel, Robin Katie Kelley, Philip Johnson, Philippe Merle, Thomas Yau, Masatoshi Kudo, Tim Meyer, Lorenza Rimassa
Summary: A systematic literature review reveals the importance of liver function assessments in predicting disease prognosis and response to systemic anticancer therapy in patients with advanced hepatocellular carcinoma. The study supports liver function as a prognostic marker and highlights the value of stratifying patients based on baseline liver function in clinical trials for aHCC.
Article
Oncology
Masatoshi Kudo, Richard S. S. Finn, Peter R. R. Galle, Andrew X. X. Zhu, Michel Ducreux, Ann-Lii Cheng, Masafumi Ikeda, Kaoru Tsuchiya, Ken-ichi Aoki, Jing Jia, Riccardo Lencioni
Summary: The study demonstrates the efficacy and safety of atezolizumab + bevacizumab treatment in patients with baseline BCLC Stage B hepatocellular carcinoma, consistent with the overall study population.
Review
Medicine, General & Internal
Yasuo Otsuka, Ken Kamata, Masatoshi Kudo
Summary: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is a useful method for diagnosing pancreatic masses. The diagnostic performance of EUS-FNA can be improved by using contrast-enhanced harmonic endoscopic ultrasonography (CH-EUS), which helps avoid fibrosis in the pancreatic mass. However, the effectiveness of CH-EUS-FNA is still a matter of debate, as only one out of eight studies showed improved sensitivity.
Article
Medicine, General & Internal
Takushi Manabe, Chikara Ogawa, Kei Takuma, Mai Nakahara, Kyoko Oura, Tomoko Tadokoro, Koji Fujita, Joji Tani, Mitsushige Shibatoge, Asahiro Morishita, Masatoshi Kudo, Tsutomu Masaki
Summary: This study validated the assessment of sarcopenia using psoas muscle volume as a measure and found that sarcopenia was associated with shorter survival in patients with liver disease. The psoas muscle volume index (PMVI) may be useful in evaluating sarcopenia, including cases where sarcopenia cannot be diagnosed using the commonly used psoas muscle index (PMI).
Article
Medicine, General & Internal
Yasuo Otsuka, Yoriaki Komeda, Masayuki Takeda, Takayuki Takahama, Masashi Kono, Mamoru Takenaka, Satoru Hagiwara, Naoshi Nishida, Hiroshi Kashida, Masatoshi Kudo
Summary: A 76-year-old woman presented with lower abdominal pain and nausea. Imaging showed a soft tissue mass extending to the liver surface, diagnosed as epithelioid mesothelioma. After chemotherapy, the patient achieved long-term survival of more than 5 years.
CASE REPORTS IN MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Tomohiro Watanabe, Kosuke Minaga, Hajime Honjo, Masatoshi Kudo
Summary: The liver showed hypo-responsiveness to antigens and high doses of orally-administered ovalbumin (OVA) generated unique CD4+ T cells and tolerogenic dendritic cells that can suppress Th1 responses. OVA administration at high doses inhibited hepatitis development in mice with OVA-specific CD4+ T cells, and this was associated with downregulation of Th1 responses. The results suggest that high-dose oral antigen administration can suppress Th1-mediated hepatitis in an antigen-non-specific manner.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Gastroenterology & Hepatology
Hiroko Iijima, Masatoshi Kudo, Shoji Kubo, Masayuki Kurosaki, Michiie Sakamoto, Shuichiro Shiina, Ryosuke Tateishi, Nakashima Osamu, Takumi Fukumoto, Yutaka Matsuyama, Takamichi Murakami, Arata Takahashi, Hiroaki Miyata, Norihiro Kokudo
Summary: Data from a nationwide follow-up survey of primary liver cancer in Japan, which compiled information from 20,889 newly registered patients and 42,274 previously registered follow-up patients, showed that patients with hepatocellular carcinoma (HCC) in the 23rd survey were older at the time of clinical diagnosis, had more female patients, had more non-B non-C HCC patients, had smaller tumor diameter, and were more frequently treated with hepatectomy compared to the previous survey. The data obtained from this survey are expected to contribute to advancing clinical research and treatment of primary liver cancer worldwide.
HEPATOLOGY RESEARCH
(2023)
Article
Oncology
Masatoshi Kudo
